Cargando…

Melatonin in the Management of Mood and Sleep Problems Induced by Androgen Deprivation Therapy in Prostate Cancer Patients: A Randomized Double-blinded, Placebo-controlled Clinical Trial

BACKGROUND: Androgen deprivation therapy (ADT) has been considered as a mainstay of treatment for advanced prostate cancer. Considering ADT for cancer patients is accompanied with many side effects, such as behavioral and neurologic side effects that adversely affect the quality of life. OBJECTIVES:...

Descripción completa

Detalles Bibliográficos
Autores principales: Etedali, Alireza, Hosseni, Amir Khayam, Derakhshandeh, Ali, Mehrzad, Valiollah, Sharifi, Mehran, Moghaddas, Azadeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Brieflands 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024317/
https://www.ncbi.nlm.nih.gov/pubmed/36942060
http://dx.doi.org/10.5812/ijpr-128817
_version_ 1784909076521549824
author Etedali, Alireza
Hosseni, Amir Khayam
Derakhshandeh, Ali
Mehrzad, Valiollah
Sharifi, Mehran
Moghaddas, Azadeh
author_facet Etedali, Alireza
Hosseni, Amir Khayam
Derakhshandeh, Ali
Mehrzad, Valiollah
Sharifi, Mehran
Moghaddas, Azadeh
author_sort Etedali, Alireza
collection PubMed
description BACKGROUND: Androgen deprivation therapy (ADT) has been considered as a mainstay of treatment for advanced prostate cancer. Considering ADT for cancer patients is accompanied with many side effects, such as behavioral and neurologic side effects that adversely affect the quality of life. OBJECTIVES: This study aimed to evaluate the effects of melatonin administration on sleep problems and mood changes induced by ADT in prostate cancer patients. METHODS: The randomized, double-blind, placebo-controlled trial was designed in the oncology-hematology outpatient clinic of Omid Hospital, Isfahan, Iran. After screening by the hospital anxiety and depression scale (HADS), patients were divided into either an intervention group receiving 6 mg melatonin daily for four weeks or an identical placebo. After that, patients were evaluated by the Pittsburgh sleep quality index (PSQI), the Hamilton Anxiety Rating Scale (HAM-A), and Beck Depression Inventory (BDI) questionnaires at baseline and after 4-week follow-ups. RESULTS: Forty-three patients, including 21 and 22 patients in melatonin and placebo groups, respectively completed follow-ups period. Melatonin administration significantly improved PSQI scores in four domains of sleep quality, sleep latency, sleep efficacy, and daytime dysfunction. After 4-week melatonin supplementation, the severity of depression and anxiety assessed by BDI and HAM-A questionnaires, respectively, decreased non-statistically significant in both melatonin and placebo groups. CONCLUSIONS: In our study, melatonin supplementation ameliorated ADT-induced sleep problems in patients with prostate cancers; however, for more conclusive results, further future large and well-designed clinical studies is warranted.
format Online
Article
Text
id pubmed-10024317
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Brieflands
record_format MEDLINE/PubMed
spelling pubmed-100243172023-03-19 Melatonin in the Management of Mood and Sleep Problems Induced by Androgen Deprivation Therapy in Prostate Cancer Patients: A Randomized Double-blinded, Placebo-controlled Clinical Trial Etedali, Alireza Hosseni, Amir Khayam Derakhshandeh, Ali Mehrzad, Valiollah Sharifi, Mehran Moghaddas, Azadeh Iran J Pharm Res Research Article BACKGROUND: Androgen deprivation therapy (ADT) has been considered as a mainstay of treatment for advanced prostate cancer. Considering ADT for cancer patients is accompanied with many side effects, such as behavioral and neurologic side effects that adversely affect the quality of life. OBJECTIVES: This study aimed to evaluate the effects of melatonin administration on sleep problems and mood changes induced by ADT in prostate cancer patients. METHODS: The randomized, double-blind, placebo-controlled trial was designed in the oncology-hematology outpatient clinic of Omid Hospital, Isfahan, Iran. After screening by the hospital anxiety and depression scale (HADS), patients were divided into either an intervention group receiving 6 mg melatonin daily for four weeks or an identical placebo. After that, patients were evaluated by the Pittsburgh sleep quality index (PSQI), the Hamilton Anxiety Rating Scale (HAM-A), and Beck Depression Inventory (BDI) questionnaires at baseline and after 4-week follow-ups. RESULTS: Forty-three patients, including 21 and 22 patients in melatonin and placebo groups, respectively completed follow-ups period. Melatonin administration significantly improved PSQI scores in four domains of sleep quality, sleep latency, sleep efficacy, and daytime dysfunction. After 4-week melatonin supplementation, the severity of depression and anxiety assessed by BDI and HAM-A questionnaires, respectively, decreased non-statistically significant in both melatonin and placebo groups. CONCLUSIONS: In our study, melatonin supplementation ameliorated ADT-induced sleep problems in patients with prostate cancers; however, for more conclusive results, further future large and well-designed clinical studies is warranted. Brieflands 2022-09-30 /pmc/articles/PMC10024317/ /pubmed/36942060 http://dx.doi.org/10.5812/ijpr-128817 Text en Copyright © 2022, Author(s) https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
spellingShingle Research Article
Etedali, Alireza
Hosseni, Amir Khayam
Derakhshandeh, Ali
Mehrzad, Valiollah
Sharifi, Mehran
Moghaddas, Azadeh
Melatonin in the Management of Mood and Sleep Problems Induced by Androgen Deprivation Therapy in Prostate Cancer Patients: A Randomized Double-blinded, Placebo-controlled Clinical Trial
title Melatonin in the Management of Mood and Sleep Problems Induced by Androgen Deprivation Therapy in Prostate Cancer Patients: A Randomized Double-blinded, Placebo-controlled Clinical Trial
title_full Melatonin in the Management of Mood and Sleep Problems Induced by Androgen Deprivation Therapy in Prostate Cancer Patients: A Randomized Double-blinded, Placebo-controlled Clinical Trial
title_fullStr Melatonin in the Management of Mood and Sleep Problems Induced by Androgen Deprivation Therapy in Prostate Cancer Patients: A Randomized Double-blinded, Placebo-controlled Clinical Trial
title_full_unstemmed Melatonin in the Management of Mood and Sleep Problems Induced by Androgen Deprivation Therapy in Prostate Cancer Patients: A Randomized Double-blinded, Placebo-controlled Clinical Trial
title_short Melatonin in the Management of Mood and Sleep Problems Induced by Androgen Deprivation Therapy in Prostate Cancer Patients: A Randomized Double-blinded, Placebo-controlled Clinical Trial
title_sort melatonin in the management of mood and sleep problems induced by androgen deprivation therapy in prostate cancer patients: a randomized double-blinded, placebo-controlled clinical trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024317/
https://www.ncbi.nlm.nih.gov/pubmed/36942060
http://dx.doi.org/10.5812/ijpr-128817
work_keys_str_mv AT etedalialireza melatonininthemanagementofmoodandsleepproblemsinducedbyandrogendeprivationtherapyinprostatecancerpatientsarandomizeddoubleblindedplacebocontrolledclinicaltrial
AT hosseniamirkhayam melatonininthemanagementofmoodandsleepproblemsinducedbyandrogendeprivationtherapyinprostatecancerpatientsarandomizeddoubleblindedplacebocontrolledclinicaltrial
AT derakhshandehali melatonininthemanagementofmoodandsleepproblemsinducedbyandrogendeprivationtherapyinprostatecancerpatientsarandomizeddoubleblindedplacebocontrolledclinicaltrial
AT mehrzadvaliollah melatonininthemanagementofmoodandsleepproblemsinducedbyandrogendeprivationtherapyinprostatecancerpatientsarandomizeddoubleblindedplacebocontrolledclinicaltrial
AT sharifimehran melatonininthemanagementofmoodandsleepproblemsinducedbyandrogendeprivationtherapyinprostatecancerpatientsarandomizeddoubleblindedplacebocontrolledclinicaltrial
AT moghaddasazadeh melatonininthemanagementofmoodandsleepproblemsinducedbyandrogendeprivationtherapyinprostatecancerpatientsarandomizeddoubleblindedplacebocontrolledclinicaltrial